

Chemotherapy Drugs

Vesicants:

Drugs capable of causing pain, inflammation and blistering of the local skin, underlying flesh and structures leading to tissue necrosis and death

Irritants:

Drugs capable of causing inflammation, irritation or pain at site of extravasation, but rarely cause tissue breakdown

Link: [Intravenous Extravasation and Management of Anti-Neoplastic Vesicant and Irritant Agents](#). Refer to Current Policy for management of extravasation.

TABLE #1

LIST OF VESICANT AND NON-VESICANT CHEMOTHERAPEUTIC AGENTS

(9/28/2018) Created by Hoag Pharmacy

VESICANT	NONVESICANT	
	IRRITANT	NON-IRRITANT
bendamustine***	aldesleukin SQ*	aldesleukin IV
Carboplatin (> 4.0mg/ml)**	arsenic trioxide	BCG
carmustine***	azacitidine*	carfilzomib
cisplatin (≥0.4 mg/mL + >20mL)**	Bleomycin*	cidofovir
dactinomycin	bortezomib	clofarabine
DAUNOrubicin	busulfan	cyclosporine
DOCEtaxel***	CABAZItaxel****	cytarabine liposomal
DOXOrubicin	Carboplatin<4mg/ml**	denileukin
etoposide**	cisplatin (<0.4 mg/mL)	eribulin
epirubicin	cladribine	fludarabine
idarubicin	cytarabine	interferon alfa 2a
mechlorethamine	cyclophosphamide	Irinotecan liposomal
Melphalan	dacarbazine*	nelarabine
mitomycin-C	DAUNOrubicin liposomal	pegaspagase
mitoxantrone***	decitabine	pemetrexed
oxaliplatin***	DOXOrubicin liposomal	pentostatin
PACLItaxel***	fluorouracil	Ziv-aflibercept
PACLITAXEL nanoparticle albumin-bound (protein bound)	floxuridine	Monoclonal Antibodies
streptozocin***	ganciclovir	• Ado-trastuzumab
vinBLASTine	gemcitabine	• alemtuzumab
vinCRISTine	lfosfamide*	• bevacizumab
vinCRISTine liposomal	irinotecan	• brentuximab
vinORELBine	ixabepilone	• cetuximab
	methotrexate*	• ipilimumab
	Mycophenolate	• panitumumab
	tacrolimus	• pertuzumab
	temozolomide	• rituximab
	teniposide*	• trastuzumab
	thiotepa	
	topotecan	

*Only rarely reported to cause necrosis/vesicant.

**Irritant that acts like a vesicant when in high concentration and large volume extravasations.

***Irritant with potential for vesicant-like properties (may need to treat as a vesicant).

****Unknown, but being a taxane, may have the potential for vesicant-like properties. In the absence of data, manage same as docetaxel and paclitaxel.

*Extravasation of large volume (>20mL) of concentrated drug (>0.5 mg/mL) may produce tissue necrosis